<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d98">
    <sentence id="DDI-DrugBank.d98.s0" text="Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;">
        <entity id="DDI-DrugBank.d98.s0.e0" charOffset="17-35"
            type="group" text="vitamin D analogues"/>
        <entity id="DDI-DrugBank.d98.s0.e1" charOffset="38-47"
            type="drug" text="Vitamin D2"/>
        <entity id="DDI-DrugBank.d98.s0.e2" charOffset="50-59"
            type="drug" text="Vitamin D3"/>
        <entity id="DDI-DrugBank.d98.s0.e3" charOffset="62-71"
            type="drug" text="Calcitriol"/>
        <entity id="DDI-DrugBank.d98.s0.e4" charOffset="78-86"
            type="drug" text="Calcidiol"/>
        <entity id="DDI-DrugBank.d98.s0.e5" charOffset="90-103"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d98.s0.e6" charOffset="106-119"
            type="drug" text="Cholestyramine"/>
        <entity id="DDI-DrugBank.d98.s0.e7" charOffset="174-193"
            type="group" text="fat soluble vitamins"/>
        <ddi id="DDI-DrugBank.d98.s0.d0" e1="DDI-DrugBank.d98.s0.e6"
            e2="DDI-DrugBank.d98.s0.e7" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s1" text="as such it may impair intestinal absorption of any of vitamin D.">
        <entity id="DDI-DrugBank.d98.s1.e0" charOffset="54-62"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s2" text="Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.">
        <entity id="DDI-DrugBank.d98.s2.e0" charOffset="0-8" type="drug" text="Phenytoin"/>
        <entity id="DDI-DrugBank.d98.s2.e1" charOffset="10-22"
            type="drug" text="Phenobarbital"/>
        <entity id="DDI-DrugBank.d98.s2.e2" charOffset="49-57"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d98.s2.e3" charOffset="62-74"
            type="drug" text="phenobarbital"/>
        <entity id="DDI-DrugBank.d98.s2.e4" charOffset="117-125"
            type="group" text="vitamin D"/>
        <entity id="DDI-DrugBank.d98.s2.e5" charOffset="171-180"
            type="drug" text="calcitriol"/>
        <ddi id="DDI-DrugBank.d98.s2.d0" e1="DDI-DrugBank.d98.s2.e2"
            e2="DDI-DrugBank.d98.s2.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d98.s2.d1" e1="DDI-DrugBank.d98.s2.e3"
            e2="DDI-DrugBank.d98.s2.e5" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s3" text="Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.">
        <entity id="DDI-DrugBank.d98.s3.e0" charOffset="21-30"
            type="drug" text="calcitriol"/>
        <entity id="DDI-DrugBank.d98.s3.e1" charOffset="80-88"
            type="brand" text="Rocaltrol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s4" text="Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.">
        <entity id="DDI-DrugBank.d98.s4.e0" charOffset="0-8"
            type="group" text="Thiazides"/>
        <entity id="DDI-DrugBank.d98.s4.e1" charOffset="11-19"
            type="group" text="Thiazides"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s5" text="Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.">
        <entity id="DDI-DrugBank.d98.s5.e0" charOffset="63-71"
            type="group" text="thiazides"/>
        <entity id="DDI-DrugBank.d98.s5.e1" charOffset="78-86"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d98.s5.d0" e1="DDI-DrugBank.d98.s5.e0"
            e2="DDI-DrugBank.d98.s5.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s6" text="Therefore, precaution should be taken when coadministration is necessary."/>
    <sentence id="DDI-DrugBank.d98.s7" text="Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.">
        <entity id="DDI-DrugBank.d98.s7.e0" charOffset="0-8"
            type="group" text="Digitalis"/>
        <entity id="DDI-DrugBank.d98.s7.e1" charOffset="11-19"
            type="group" text="Vitamin D"/>
        <entity id="DDI-DrugBank.d98.s7.e2" charOffset="95-103"
            type="group" text="digitalis"/>
        <ddi id="DDI-DrugBank.d98.s7.d0" e1="DDI-DrugBank.d98.s7.e1"
            e2="DDI-DrugBank.d98.s7.e2" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s8" text="Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.">
        <entity id="DDI-DrugBank.d98.s8.e0" charOffset="0-11"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d98.s8.e1" charOffset="14-25"
            type="drug" text="Ketoconazole"/>
        <entity id="DDI-DrugBank.d98.s8.e2" charOffset="79-87"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d98.s8.d0" e1="DDI-DrugBank.d98.s8.e1"
            e2="DDI-DrugBank.d98.s8.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s9" text="Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.">
        <entity id="DDI-DrugBank.d98.s9.e0" charOffset="133-144"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s10" text="However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.">
        <entity id="DDI-DrugBank.d98.s10.e0" charOffset="45-56"
            type="drug" text="ketoconazole"/>
        <entity id="DDI-DrugBank.d98.s10.e1" charOffset="63-71"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s11" text="Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.">
        <entity id="DDI-DrugBank.d98.s11.e0" charOffset="0-14"
            type="group" text="Corticosteroids"/>
        <entity id="DDI-DrugBank.d98.s11.e1" charOffset="72-90"
            type="group" text="vitamin D analogues"/>
        <entity id="DDI-DrugBank.d98.s11.e2" charOffset="131-145"
            type="group" text="corticosteroids"/>
        <ddi id="DDI-DrugBank.d98.s11.d0" e1="DDI-DrugBank.d98.s11.e1"
            e2="DDI-DrugBank.d98.s11.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s12" text="Phosphate-Binding Agents: Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.">
        <entity id="DDI-DrugBank.d98.s12.e0" charOffset="32-40"
            type="group" text="vitamin D"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s13" text="Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.">
        <entity id="DDI-DrugBank.d98.s13.e0" charOffset="0-8"
            type="group" text="Vitamin D"/>
        <entity id="DDI-DrugBank.d98.s13.e1" charOffset="46-64"
            type="group" text="vitamin D analogues"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s14" text="Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.">
        <entity id="DDI-DrugBank.d98.s14.e0" charOffset="0-6"
            type="drug" text="Calcium"/>
        <entity id="DDI-DrugBank.d98.s14.e1" charOffset="55-61"
            type="drug" text="calcium"/>
    </sentence>
    <sentence id="DDI-DrugBank.d98.s15" text="Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.">
        <entity id="DDI-DrugBank.d98.s15.e0" charOffset="0-8"
            type="drug" text="Magnesium"/>
        <entity id="DDI-DrugBank.d98.s15.e1" charOffset="11-19"
            type="drug" text="Magnesium"/>
        <entity id="DDI-DrugBank.d98.s15.e2" charOffset="50-57"
            type="group" text="antacids"/>
        <entity id="DDI-DrugBank.d98.s15.e3" charOffset="140-148"
            type="group" text="vitamin D"/>
        <ddi id="DDI-DrugBank.d98.s15.d0" e1="DDI-DrugBank.d98.s15.e1"
            e2="DDI-DrugBank.d98.s15.e3" type="advise"/>
        <ddi id="DDI-DrugBank.d98.s15.d1" e1="DDI-DrugBank.d98.s15.e2"
            e2="DDI-DrugBank.d98.s15.e3" type="advise"/>
    </sentence>
</document>
